Why refractory epilepsy in dogs is getting renewed attention

A new Veterinary Practice News Education Center article is putting fresh attention on one of small animal neurology’s hardest problems: why some dogs keep seizing even after treatment starts. Published June 1, 2026, and written by veterinary neurologist Simon R. Platt, the piece focuses on refractory, or drug-resistant, epilepsy in dogs and makes a clear clinical point: seizure freedom should remain the goal, even when partial improvement may feel like progress in difficult cases. (veterinarypracticenews.com)

That framing reflects a broader shift in veterinary epilepsy management over the past decade. The International Veterinary Epilepsy Task Force has defined drug-resistant epilepsy in dogs using a standard familiar from human medicine: failure of adequate trials of two tolerated, appropriately chosen anti-seizure drug regimens to achieve sustained seizure freedom. That definition matters because it pushes clinicians to distinguish true pharmacoresistance from lookalike problems such as underdosing, poor adherence, inadequate monitoring, misclassification of seizure type, or an incorrect underlying diagnosis. (pmc.ncbi.nlm.nih.gov)

Platt’s article says about 30% of dogs with idiopathic epilepsy are resistant to one or more anti-seizure medications and highlights several suspected contributors, including breed-related risk, high early seizure frequency, and drug tolerance over time. The article also stresses that refractory cases need ongoing care, regular rechecks, and detailed seizure logs to help fine-tune therapy. That aligns with frontline guidance from Cornell, which notes that some dogs will need more than one medication, that levetiracetam is commonly added as a second drug, and that tolerance can complicate long-term control in previously stable patients. (veterinarypracticenews.com)

Additional research supports the article’s emphasis on multimodal management rather than relying only on dose escalation. Several controlled studies have found that medium-chain triglyceride supplementation or MCT-enriched diets can reduce seizure frequency in some dogs with idiopathic epilepsy, including dogs already receiving anti-seizure drugs. Those findings don’t make diet a replacement for standard therapy, but they do support its role as a practical adjunct, especially in chronic cases where side effects, caregiver burden, and incomplete control are all in play. (pubmed.ncbi.nlm.nih.gov)

Industry and specialist commentary also show how much these cases affect day-to-day practice. In a Vet Times podcast, neurologist Mark Lowrie said refractory epilepsy affects about one in three dogs with epilepsy and pointed to dietary modification, including MCT-based approaches, as a low-side-effect option that can help some patients. In February 2026, PRN Pharmacal parent Pegasus announced full FDA approval for KBroVet, a potassium bromide chewable tablet indicated for control of seizures associated with idiopathic epilepsy in dogs. In that announcement, neurologist Fred Wininger described the heavy toll epilepsy can take on households, from sleep disruption to constant anticipation of the next seizure. (vettimes.com)

Why it matters: For general practitioners and emergency teams, refractory epilepsy is less a niche neurology topic than a care-management challenge that touches diagnosis, communication, and compliance. These are the dogs that return for breakthrough seizures, cluster events, adverse-effect concerns, or pet parent fatigue. The practical takeaway is to reassess the basics before labeling a case hopeless: confirm the diagnosis, revisit whether the seizure pattern suggests idiopathic versus structural disease, verify dosing and timing, use therapeutic drug monitoring where appropriate, and ask whether rescue plans for home use are in place. Cornell’s guidance on rectal diazepam, intranasal midazolam, and pulse levetiracetam for cluster-prone dogs illustrates how much quality of life can hinge on a well-built outpatient plan. (vet.cornell.edu)

The article also arrives at a moment when the treatment landscape is inching forward, even if no single breakthrough has solved refractory disease. The KBroVet approval gives veterinarians a fully FDA-approved potassium bromide option in a category long managed with compounded, extra-label, or older standard therapies, and it may sharpen attention on evidence, monitoring, and product consistency. Still, the larger message from the sponsored article and the outside literature is the same: refractory epilepsy remains common, heterogeneous, and frustrating, which means individualized management, realistic counseling, and long-term follow-up are still the core of care. (prnewswire.com)

What to watch: The next phase to watch is whether newer labeled therapies, better phenotyping of high-risk breeds and early-course patients, and broader use of adjuncts such as MCT-based nutrition can move more dogs from “reduced seizures” toward sustained seizure freedom. (veterinarypracticenews.com)